Rate My Professor Trevor Thompson

Trevor Thompson is an Associate Professor of Clinical Research in the School of Human Sciences within the Faculty of Education, Health and Human Sciences at the University of Greenwich, a position he has held since 2008. Prior to this, he served as a Research Fellow at Goldsmiths, University of London from 2006 to 2008. Thompson holds a BSc (Hons), MSc, and PhD, and is a Fellow of the Royal Statistical Society. His primary academic interests lie in health and neuroscience, particularly pain management, and the application of advanced statistical methods to clinical research challenges. He has made substantial contributions through numerous peer-reviewed publications in prestigious journals such as JAMA Psychiatry, Neurology, Ageing Research Reviews, and Pain, amassing over 11,000 citations as per Google Scholar metrics. These works underscore his expertise in conducting systematic reviews, network meta-analyses, and investigations into mental health outcomes.

Thompson's recent publications highlight his influence across diverse areas of clinical research. Key examples include co-authoring 'AVATAR versus cognitive-behavioral therapy for medication-resistant auditory hallucination: a systematic review and network meta-analysis' in Psychological Medicine (2026), 'Effects of Nandrolone Decanoate on muscle strength, body composition and bone density: a systematic review and meta-analysis' in the Journal of Cachexia, Sarcopenia and Muscle (2026), and 'Health related behaviour patterns in Denmark during the first COVID-19 wave' in Discover Public Health (2026). Additional impactful papers cover suicide risk on specific holidays in Frontiers in Public Health (2025), response trajectories of viloxazine treatment for ADHD in JAMA Network Open (2024), mental health trajectories during COVID-19 in multiple countries via the COH-FIT study published in the Journal of the American Academy of Child & Adolescent Psychiatry (2024), and placebo bias in delirium prevention trials in Psychiatry and Clinical Neurosciences (2025). His research on topics ranging from pharmacological interventions and pandemic-related behavioral changes to dissociative states and anti-amyloid therapies for Alzheimer’s disease demonstrates a broad impact on advancing evidence-based clinical practices in neuroscience, psychiatry, and public health.